×
About 40,276 results
Fasting Triglycerides & Glucose Index: A Useful Screening Test for Assessing Insulin Resistance in Patients Diagnosed with Rheumatoid Arthritis & Systemic Lupus Erythematosus
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0495-x
Diabetology & Metabolic Syndrome; Contreras-Haro B, et al

Nov 26th, 2019 - Insulin resistance (IR) is frequently observed in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). In clinical practice, IR assessment is limited to a low proportion of patients due to cost and equipment and technical expertise requirements. The surrogate index of triglycerides and glucose (TyG index) has been validated in non-rheumatic populations, showing adequat...

Statement on efforts to help make development of biosimilar and interchangeable insulin products more efficient
https://www.fda.gov/news-events/press-announcements/statement-efforts-help-make-development-biosimilar-and-interchangeable-insulin-products-more
FDA

Nov 24th, 2019 - Access to affordable insulin can be a matter of life and death for Americans with diabetes. If not appropriately treated, diabetes can lead to serious and life-threatening complications, including heart disease, organ failure and blindness. And consistent, lifelong access to insulin is imperative to patient survival and quality of life. However, we are aware that the high cost of insulin raises...

Medtronic Recalls Remote Controllers for MiniMed Insulin Pumps for Potential Cybersecurity Risks
https://www.fda.gov/medical-devices/medical-device-recalls/medtronic-recalls-remote-controllers-minimed-insulin-pumps-potential-cybersecurity-risks
FDA

Nov 20th, 2019 - Medtronic is recalling the specified remote controllers due to potential cybersecurity risks. An unauthorized person (someone other than a patient, patient caregiver, or health care provider) could potentially record and replay the wireless communication between the remote and the MiniMed insulin pump. Using specialized equipment, an unauthorized person could instruct the pump to either over-d...

High-protein Diet is Bad for Kidney Health: Unleashing the Taboo
https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfz216/5614387
Nephrology Dialysis Transplantation; Kalantar-Zadeh K, et al

Nov 6th, 2019 - How often have you been told to eat more protein and less carbohydrates to stay healthy? This is not an emerging food culture but rather a prevailing dogma in our society. Physicians, dietitians and other health care professionals tell us constantly about the advantages of a high-protein diet (HPD), such as losing weight rapidly, burning calories, diminishing appetite, preventing obesity, manag...

Scientists design device for oral delivery of injections
https://www.nih.gov/news-events/nih-research-matters/scientists-design-device-oral-delivery-injections

Oct 28th, 2019 - Biologic drugs are complex medications produced from living organisms or their parts. They include vaccines and drugs to treat conditions like rheumatoid arthritis, psoriasis, and cancer. Some biologic drugs, like insulin, can only be delivered by injection. If taken by mouth, stomach acid would destroy the drug before it could take effect.

Pediatric Metabolic and Bariatric Surgery: Evidence, Barriers, and Best Practices
https://pediatrics.aappublications.org/content/early/2019/10/24/peds.2019-3223
Pediatrics Armstrong, S. et. al.

Oct 27th, 2019 - Severe obesity among youth is an “epidemic within an epidemic” and portends a shortened life expectancy for today’s children compared with those of their parents’ generation. Severe obesity has outpaced less severe forms of childhood obesity in prevalence, and it disproportionately affects adolescents. Emerging evidence has linked severe obesity to the development and progression of multiple co...

FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122974

Oct 21st, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.1 Fiasp®, a rapid-acting insulin, was approved by the FDA in 2017 for use by intravenous infusion under supervision by a health...

Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
https://www.gene.com/media/press-releases/14817/2019-10-17/genentech-announces-fda-approval-of-xofl

Oct 16th, 2019 - Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease, morbid obesity or adults ...

Weight change across adulthood in relation to all cause and cause specific mortality: prospective cohort study
https://www.bmj.com/content/367/bmj.l5584
BMJ Chen, C. et. al.

Oct 15th, 2019 - Objective To investigate the association between weight changes across adulthood and mortality. Design Prospective cohort study. Setting US National Health and Nutrition Examination Survey (NHANES) 1988-94 and 1999-2014. Participants 36 051 people aged 40 years or over with measured body weight and height at baseline and recalled weight at young adulthood (25 years old) and middle adul...

Association of Cardiovascular Disease With Premature Mortality in the United States
https://jamanetwork.com/journals/jamacardiology/fullarticle/2752889
JAMA Cardiology; Chen, Y. et. al.

Oct 15th, 2019 - Question How have the trends in premature mortality from cardiovascular disease (CVD) changed in the United States during 2000 to 2015 by demographics and county-level factors, including education, rurality, and the prevalence of smoking, obesity, and diabetes? Findings In this study, CVD mortality rates increased significantly among American Indian/Alaska Native individuals age 25 to 49 y...

Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations
https://academic.oup.com/jes/article/3/10/1942/5581189
Journal of the Endocrine Society;

Oct 6th, 2019 - Faster-acting insulins, new noninsulin drug classes, more flexible insulin-delivery systems, and improved continuous glucose monitoring devices offer unprecedented opportunities to improve postprandial glucose (PPG) management and overall care for adults with insulin-treated diabetes. These developments led the Endocrine Society to convene a working panel of diabetes experts in December 2018 to...

Sleeping less than six hours and heart disease, stroke – deadly combo
https://newsroom.heart.org/news/sleeping-less-than-six-hours-and-heart-disease-stroke-deadly-combo

Oct 1st, 2019 - Middle-aged adults with high blood pressure, Type 2 diabetes, heart disease or stroke could be at increased risk for cancer and early death when sleeping less than 6 hours per day.

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
http://www.onlinejacc.org/content/74/15/1926?_ga=2.47888103.1317319445.1570642054-675541502.1568116402
Journal of the American College of Cardiology; Shapiro, M. et. al.

Oct 1st, 2019 - Although significant progress has been made to reduce the global burden of cardiovascular disease, efforts have focused primarily on treatment of manifest disease rather than on prevention of events. An enormous opportunity exists to transition focus from intervention to providing equal attention to prevention of cardiovascular disease. The nascent specialty of “preventive cardiology” is emergi...

U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD
https://www.janssen.com/us-fda-approves-invokana-canagliflozin-treat-diabetic-kidney-disease-dkd-and-reduce-risk

Sep 29th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for INVOKANA® (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic kidney disease (nephropa...

Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq

Sep 24th, 2019 - Pheochromocytoma and paraganglioma treatment is usually surgery, however, preoperative medical preparation is critical. Palliative care for metastatic disease may include chemotherapy, radiation therapy, targeted therapy, and other modalities. Get detailed information in this clinician summary.

Screening and Management of the Hyperandrogenic Adolescent
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-the-Hyperandrogenic-Adolescent

Sep 23rd, 2019 - Although androgen excess can manifest in many ways, the most common and recognizable symptoms are hirsutism and acne. Reports of hirsutism and acne should be taken seriously because of their possible association with medical disorders, their substantial effect on self-esteem and quality of life, and the potential for psychosocial morbidity. In patients with symptoms of androgen excess, the diff...

FDA approves first oral GLP-1 treatment for type 2 diabetes
https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes

Sep 19th, 2019 - The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. GLP-1 drugs are non-insulin treatments for people wi...

FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122973

Sep 19th, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).1 Rybelsus® is the first and only glucagon-like peptide-1 (GLP-1) analog in a pill and a new option for adults with type 2 diabetes who are not achieving their ...

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
The New England Journal of Medicine; McMurray, J. et. al.

Sep 18th, 2019 - BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 ...

Lipoprotein(a): The Next Promising CVD Risk Assessment Tool and Prevention Target Among the High-risk Population
https://www.acc.org/latest-in-cardiology/articles/2019/09/17/15/02/lipoprotein-a

Sep 17th, 2019 - After low density lipoprotein cholesterol (LDL-C) has been targeted to reduce cardiovascular disease (CVD) risk, other novel lipid biomarkers have become the center of attention of investigation, and on-going clinical trials are targeting these lipid markers trying to lower the so-called "residual CVD risk" in addition to conventional lipid-lowering therapy. Among them, serum lipoprotein(a) [Lp...

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30311-0/fulltext
The Lancet Diabetes & Endocrinology; Lingvay, I. et. al.

Sep 16th, 2019 - Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibitors are increasingly used as second-line agents, direct comparisons between these treatments are insufficient. In the SUSTAIN 8 trial, we compared the...

New CDC Obesity Prevalence Maps: Nine states report adult obesity at or above 35 percent
https://www.cdc.gov/media/releases/2019/s0912-obesity-prevalence-maps.html

Sep 11th, 2019 - In 2018, nine states reported an adult obesity prevalence at or above 35 percent: Alabama, Arkansas, Iowa, Kentucky, Louisiana, Mississippi, Missouri, North Dakota, and West Virginia. This comes from the new obesity prevalence maps released today by the Centers for Disease Control and Prevention.

Xeris Pharmaceuticals Receives U.S. Fda Approval For Gvoke™ (Glucagon), The First Ready-to-use Stable Liquid Glucagon For Severe Hypoglycemia
https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon

Sep 9th, 2019 - Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) for GVOKE™ (glucagon) injection, its ready-to-use, room-temperature stable liquid gl...

Patient-Physician Agreement in Reporting and Prioritizing Existing Chronic Conditions
http://www.annfammed.org/content/17/5/396.full
Annals of Family Medicine;

Sep 9th, 2019 - PURPOSE In this study, we aimed to assess (1) the agreement between patient self-reports and general practitioner (GP) reports of the chronic conditions affecting the patients and (2) the agreement between patients and GPs on health priorities in a primary care setting. METHOD Patients were recruited in the Parisian area of France by a convenience sample of GPs; eligibility criteria required...

Laparoscopic management of a migrated intragastric balloon causing mechanical small bowel obstruction: a case report and review of the literature
https://publishing.rcseng.ac.uk/doi/abs/10.1308/rcsann.2019.0104
Annals of The Royal College of Surgeons of England; Hay D, et al

Sep 5th, 2019 - Intragastric balloons have been used as an invasive non-surgical treatment for obesity for over 30 years. Within the last 37 years, we have found only 27 cases reported in the literature of intestinal obstruction caused by a migrated intragastric balloon. We report the laparoscopic management of such a case and make observations from similar case presentations published in the literature. A ...

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-Bleeding-Disorders-in-Adolescents-With-Heavy-Menstrual-Bleeding

Aug 21st, 2019 - Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they should work in coordination with a hematologist for laboratory evaluation and medical management. Evaluation of adolescent girls who present with heavy men...

Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes
https://annals.org/aim/fullarticle/2748278/diabetes-technology-review-2019-american-diabetes-association-standards-medical-care
Annals of Internal Medicine;

Aug 12th, 2019 - Description: The American Diabetes Association (ADA) annually updates its Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: The ADA Professional Practice Committee comprises physicians, adult and pediatric endocrinol...

Should Adults With Prediabetes Be Prescribed Metformin To Prevent Diabetes Mellitus? Yes: High-Quality Evidence Supports Metformin Use in Persons at High Risk
https://www.aafp.org/afp/2019/0801/p134.html
American Family Physician; Moin, T.

Aug 1st, 2019 - A surge in the prevalence of prediabetes1 highlights the importance of improving prediabetes awareness and engaging in strategies to lower the risk of type 2 diabetes mellitus. Based on evidence from randomized controlled trials and observational studies, U.S. and international guidelines advocate for the use of medications in addition to intensive lifestyle interventions to prevent diabetes.2,...

Hirsutism in Women
https://www.aafp.org/afp/2019/0801/p168.html

Jul 31st, 2019 - Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female. It is often a sign of excessive androgen levels. Although many conditions can lead to hirsutism, polycystic ovary syndrome and idiopathic hyperandrogenism account for more than 85% of cases. Less common causes include idiopathic hirsutism, nonclassic congenital adrenal hyperplasia, androgen-secreting tumor...

Living Standards of Medical Care in Diabetes
https://care.diabetesjournals.org/living-standards

Jul 30th, 2019 - The American Diabetes Association’s (ADA’s) Standards of Medical Care in Diabetes (Standards of Care) provide the latest in comprehensive, evidence-based recommendations for the diagnosis and treatment of children and adults with type 1, type 2 or gestational diabetes; strategies to prevent or delay type 2 diabetes; and therapeutic approaches that reduce complications and positively affect heal...

Updates to the 2019 Standards of Medical Care in Diabetes Issued Today by the American Diabetes Association
http://www.diabetes.org/newsroom/press-releases/2019/updates-standards-medical-care.html

Jul 30th, 2019 - The American Diabetes Association® (ADA) issued important updates to the 2019 Standards of Medical Care in Diabetes (Standards of Care) today, in annotations as the Living Standards of Care, with the changes focusing on new metrics for continuous glucose monitoring (CGM) utilization and new medication options and recommendations for youth and adults with type 2 diabetes. The updates were inform...

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study
https://annals.org/aim/article-abstract/2739786/sodium-glucose-cotransporter-2-inhibitors-risk-severe-urinary-tract-infections
Annals of Internal Medicine;

Jul 29th, 2019 - Background: Prior studies evaluating risk for severe urinary tract infections (UTIs) with sodium–glucose cotransporter-2 (SGLT-2) inhibitors have reported conflicting findings. Objective: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like...

Pulse waves measured at the wrist uncover often-missed artery changes in menopausal women
https://newsroom.heart.org/news/pulse-waves-measured-at-the-wrist-uncover-often-missed-artery-changes-in-menopausal-women

Jul 28th, 2019 - Measuring a menopausal woman’s pulse wave at her wrist can detect circulatory system changes that aren’t evident with blood pressure readings. Menopause’s effect on these radial pulse wave harmonics can help explain why women in menopause are at heightened cardiovascular disease risk.

New Approaches Improve Diagnosis, Prediction of Type 2 Diabetes
https://www.patientcareonline.com/t2-diabetes/new-approaches-improve-diagnosis-prediction-type-2-diabetes

Jul 25th, 2019 - The accuracy of diagnosing and predicting type 2 diabetes mellitus (T2DM) and prediabetes could be improved by applying multiple or alternative measures, according to studies presented at the American Diabetes Association (ADA) Scientific Sessions meeting in San Francisco, CA, in June. Joon Ha, PhD, Laboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Disea...

BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
https://investor.lilly.com/news-releases/news-release-details/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally

Jul 23rd, 2019 - The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli Lilly and Company (NYSE: LLY) announced today. BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind. It is compact, portable and ready to ...

Recent Research on the Health Benefits of Blueberries and Their Anthocyanins
https://academic.oup.com/advances/advance-article/doi/10.1093/advances/nmz065/5536953?searchresult=1
Advances in Nutrition; Kalt, W. et. al.

Jul 21st, 2019 - Awareness of the human health benefits of blueberries is underpinned by a growing body of positive scientific evidence from human observational and clinical research, plus mechanistic research using animal and in vitro models. Blueberries contain a large number of phytochemicals, including abundant anthocyanin pigments. Of their various phytochemicals, anthocyanins probably make the greatest im...

Randomized Controlled Phase 2a Study of RPh201 in Previous Nonarteritic Anterior Ischemic Optic Neuropathy
https://journals.lww.com/jneuro-ophthalmology/Abstract/publishahead/Randomized_Controlled_Phase_2a_Study_of_RPh201_in.99147.aspx
Rath, E. et. al.

Jul 21st, 2019 - Background: No proven treatment exists for nonarteritic anterior ischemic optic neuropathy (NAION), either in the acute or late phase. Objective: To assess safety and changes in visual function and structure after RPh201/placebo treatment in participants with previous NAION. Design and Setting: Phase 2a, single-site, prospective, randomized, placebo-controlled, double-masked trial (regist...

Obesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504569/

Jul 12th, 2019 - Our objective was to compare obesity prevalence among human immunodeficiency virus (HIV)-infected adults receiving care and the U.S. general population and identify obesity correlates among HIV-infected men and women. Cross-sectional data was collected in 2009 to 2010 from 2 nationally representative surveys: Medical Monitoring Project (MMP) and National Health and Nutrition Examination Surv...

FDA warns patients and health care providers about potential cybersecurity concerns with certain Medtronic insulin pumps
https://www.fda.gov/news-events/press-announcements/fda-warns-patients-and-health-care-providers-about-potential-cybersecurity-concerns-certain

Jun 26th, 2019 - The U.S. Food and Drug Administration is warning patients and health care providers that certain Medtronic MiniMed insulin pumps are being recalled due to potential cybersecurity risks and recommends that patients using these models switch their insulin pump to models that are better equipped to protect against these potential risks. To date, the FDA is not aware of any confirmed reports of pat...

FDA approves new treatment for pediatric patients with type 2 diabetes
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-type-2-diabetes

Jun 16th, 2019 - The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.

Vitamin D Supplementation and Prevention of Type 2 Diabetes
https://www.nejm.org/doi/10.1056/NEJMoa1900906
New England Journal of Medicine; Pittas. A., et al

Jun 6th, 2019 - Observational studies support an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes. However, whether vitamin D supplementation lowers the risk of diabetes is unknown. METHODS We randomly assigned adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose level 2 hou...

Varicose Veins: Diagnosis and Treatment.
https://www.aafp.org/afp/2019/0601/p682.html
American Family Physician; Raetz, J. et. al.

May 31st, 2019 - Varicose veins are twisted, dilated veins most commonly located on the lower extremities. The exact pathophysiology is debated, but it involves a genetic predisposition, incompetent valves, weakened vascular walls, and increased intravenous pressure. Risk factors include family history of venous disease; female sex; older age; chronically increased intra-abdominal pressure due to obesity, pregn...

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
http://care.diabetesjournals.org/content/42/6/1147
Diabetes Care; Danne, T. et. al.

May 31st, 2019 - Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolut...

Management of Acute Obstructive Uterovaginal Anomalies
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Management-of-Acute-Obstructive-Uterovaginal-Anomalies

May 22nd, 2019 - ABSTRACT: Obstructive uterovaginal anomalies may present after puberty with amenorrhea, dysmenorrhea, pelvic pain, recurrent vaginal discharge, or infertility. The evaluation of a patient with a suspected obstructive reproductive anomaly should include a detailed medical history, physical examination, and imaging. The genital examination is critical to differentiate a patient with an imperforat...

Preventable Cancer Burden Associated with Poor Diet in the United States
https://academic.oup.com/jncics/advance-article/doi/10.1093/jncics/pkz034/5492023
Cancer Spectrum; Zhang, F. et. al.

May 21st, 2019 - Diet is an important risk factor for cancer that is amenable to intervention. Estimating the cancer burden associated with diet informs evidence-based priorities for nutrition policies to reduce cancer burden in the US. Methods Using a Comparative Risk Assessment model that incorporated nationally representative data on dietary intake, national cancer incidence, and estimated associations o...

FDA Approves Eylea (Aflibercept) Injection For Diabetic Retinopathy
https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-diabetic-retinopathy

May 12th, 2019 - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness. "Millions of people have been robbed of their vision due to the progression of diabetic retinopathy," said David Brown, M.D., F.A.C.S., an investi...

Metformin | PubChem
https://pubchem.ncbi.nlm.nih.gov/compound/metformin

May 10th, 2019 - A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification.

Transcultural Diabetes Care in the United States
https://journals.aace.com/doi/pdf/10.4158/PS-2019-0080

May 7th, 2019 - The American Association of Clinical Endocrinologists (AACE) has created a transculturalized diabetes chronic disease care model that is adapted for patients across a spectrum of ethnicities and cultures. AACE has conducted several transcultural activities on global issues in clinical endocrinology, and completed a 3-city series of conferences in December 2017 that focused on diabetes care for ...

Metformin - Metformin - LiverTox - NIH
https://livertox.nih.gov/Metformin.htm

Apr 30th, 2019 - Metformin is a first line agent for the treatment of type 2 diabetes that can be used alone or in combination with sulfonylureas, thiazolidinediones or other hypoglycemic agents. Metformin has not been linked to serum enzyme elevations during therapy and is an exceeding rare cause of idiosyncratic clinically apparent acute liver injury.